Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS2577978 A
Publication typeGrant
Publication dateDec 11, 1951
Filing dateFeb 4, 1949
Priority dateFeb 4, 1949
Publication numberUS 2577978 A, US 2577978A, US-A-2577978, US2577978 A, US2577978A
InventorsFonner Dale E, Nicholls Richard S
Original AssigneeMiles Lab
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Diagnostic composition
US 2577978 A
Abstract  available in
Images(3)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

Patented Dec. 11, 1951 l'i'ED STTES ATENT FFICE DIAGNOSTIC COMPOSITION No Drawing. Application February 4, 1949, Serial No. 74,706

9 Claims.

The present invention relates to new and improved diagnostic compositions useful for the qualitative detection and quantitative estimation of ketone bodies in body fluids, particularly acetone bodies in the urine.

More specifically, the invention relates to diagnostic compositions in solid dry form, preferably tableted in suitable sized tablets, which composition can readily be used, even by unskilled persons, rapidly to detect the presence of acetone in urine without evolvement of ammonia, with ready distinction between positive and negative tests, and without the use of equipment or apparatus other than some means of obtaining a drop of test fluid.

In the metabolism of fat, acetone bodies or ketone bodies are regarded as normal intermediate compounds which are subsequently oxidized to carbon dioxide and water. The ketone bodies include acetone, acetoacetic acid (beta-ketchutyric acid or diacetic acid) and beta-hydroxybutyric acid. Under normal circumstances, no significant ouantity of these ketone substances appears in the urine. However, if there is an excessive metabolism of fat, the intermediate acetone bodies accumulate in the blood and are excreted in the urine in variable amounts. In diabetes mellitus such an excessive fat metabolism occurs and many of the symptoms of this disease can be ascribed to the toxic effects of the acetone bodies. The medical profession is well aware of the usefulness in diagnosis of tests for acetone bodies in the urine in diabetes mellitus cases. Acetone bodies also occur in the urine in other well recognized disturbances of the metabolism, and in such cases it is also important to carry out tests for detection of these substances.

A variety of reagents and techniques have been used or proposed in the past for the detection of acetone bodies in urine. A number of such reagents and technicues have involved the use of a water soluble nitroprusside as a reactive ingredient or agent. In one particular reagent formulation, the nitroprusside reaction is carried out in the presence of ammonia in order to develop particu ar colorations (see United States Patent No. 2.186902 to Fortune). An improvement over the Fortune tvpe formulation is disclosed in copending application Serial No. 12.699, filed March 2, 1948, now Patent No. 2509,140 issued on May 23, 1950. by Alfred H. Free, assigned to the assi nee of t e present application. Application Serial No. 12.699 discloses formulations for detection of acetone bo ies in the urine which contain water soluble nitroprusside, an aliphatic amino acid and an alkaline material.

2 It was found, according to application Serial No. 12,699, that when the soluble nitroprusside is present in alkaline solution with an aliphatic amino acid (e. g. glycine), a diagnostic composition is provided which is particularly adapted for the detection of acetone bodies in urine without evolvement of ammonia.

According to the present invention, it has been discovered that the addition of lactose to the diagnostic formulation set forth in application Serial No. 12,699 greatly enhances the usefulness and reliability of that type of diagnostic formulation.

The object of the present invention, generally stated, is the provision of improved diagnostic compositions in stable dry form, preferably as tablets, which can be used even by an unskilled person conveniently to give an accurate quali-- tative test for, and a quantitative estimation of. the presence of acetone bodies in urine, which test clearly distinguishes between positive and negative specimens, even when the quantity of acetone is small, so as to give only what is known as a trace positive.

An important object of the invention is the provision of a stable dry diagnostic composition for the detection of acetone bodies in urine which contains a water-soluble nitroprusside, an aliphatic amino acid, and an alkaline material, as active in redients, and in addition contains lactose which serves to prevent color change in the case of acetone-negatives and to keep the colors in the whole range of positives very truly and characteristically lavender, so that there will be no chance for confusion between positive and negative specimens, even where there are only trace amounts of acetone bodies in the positives.

Other obiectsof the invention will in part be obvious and will in part appear hereinafter.

The following example discloses a presently preferred embodiment of the invention.

Example I The following formulation is uniformly composed by known blending and mixing techniques,

In use, a drop of the urine specimen to be tested is dropped onto a tablet made from the above formulation. If the specimen contains acetone bodies, a characteristic and definite lavender coloration is quickly produced which is highly characteristic and specific to acetone positive specimens. Trace positives (i. e. positive specimens with only a trace amount of acetone bodies), will also give this characteristic lavender coloration.

The depth of the shade or hue of the lavender coloration can be used as a basis for estimating quantitatively the amount of acetone bodies present in the specimen. Thus, a color chart may be supplied which is graduated into different shades or hues of lavender corresponding to known concentrations of acetone bodies. By using such a chart in connection with the testin of a specimen, not only can a determination be made as to whether or not a specimen is negative or positive, but further, positive specimens can be compared with the standard color chart to obtain a fairly accurate estimation of the quantity of acetone bodies present.

The application of a negative specimen to a lactose-free test tablet or composition causes the tablet, or composition, to take on a gold coloration which progressively changes a brown shade as time passes. A po itive specimen applied to a lactose-free test tablet produces a lavender coloration which, with the passage of time becomes muddied with brown.

Not only do the lactose containing tablets result in the production of a stable cream color when negative specimens are applied thereto, but in the case of positive reactions a true lavender color is obtained which remains constant for 15 to 30 minutes or more, after the maximum color intensity is reached. Thus an important advantage of a lactose-containing composition, as hereinbefore described, lies in the fact that the time within which a test must be read is substantially extended. Furthermore, since the hue of the final color is stable, the use of a color chart is made much less difficult and more accurate than heretobefore.

The fact that no color changes are obtained with negative specimens when the formulations of the present invention are used is an important feature of particular significance in litigation cases where the reliability of an acetone test is brou ht under close scrutiny. Obviously, the reliability and probative value of any test procedure is greatly enhanced if it can be unequivocally testified that no coloration is obtained with a ne ative specimen on the one hand, whereas all positive specimens give a characteristic lavender coloration on the other hand. Such testimony is much more forceful and influential than testimony in which it would be necessary to state that coloration is obtained even with negative specimens, but such coloration is different from that obtained with positive specimens.

Example 2 By omitting the sodium borate, corn starch and magnesium stearate from the formulation in Example 1, a dry powder formulation may be prepared which, as such, issuitable for use in the detection of acetone bodies in urine. However, it is not adapted to be tableted.

Although the formulation set forth in Example 1 is the presently preferred one for the preparation of reaction test tablets, and the formulation set forth in Example 2 is the p2 ferred one for reaction test powder, it will be understood that those skilled in the art will be able to prepare a large number of other specific formulations embodying our present invention, but which may be somewhat different in respect to specific proportions than the formulations set forth in Examples 1 and 2.

In our formulations, the reactive ingredients may be considered to be the water-soluble nitroprusside, and the aliphatic amino acid. For practical purposes and availability, sodium nitroprusside is the preferred soluble nitroprusside and glycine is the preferred aliphatic amino acid. However, all of the alkali metal nitroprussides are water soluble, and any one of them may be used such, for example, as the potassium nitroprusside. Thus, potassium nitroprusside in a molecularly equivalent amount may be substituted for the sodium nitroprusside in Examples 1 and 2. The glycine may be replaced with another aliphatic amino acid such as alanine, glutamic acid, arginine, aspartic acid and lysine.

In addition to the amino acid and the watersoluble nitroprusside, two other ingredients are essential in our formulations. One is an alkaline material which is necessary in order to have the test reaction carried out under alkaline conditions. Generally, any alkaline material which will produce this result may be used, it of course being necessary that the alkaline material be one that permits the preparation and storage of a stable diagnositic composition, which does not interfere with the test reaction, and which is not reactive with either the glycine or the soluble nitroprusside. Although anhydrous disodium phosphate is the preferred alkaline material for use in our reagent test compositions, other dry alkaline solids which may be used include, the alkalimetal carbonates and hydroxides, trisodium phosphate, dipotassium phosphate, and the like. Instead of using a single alkaline ingredient, it is possible to use a mixture of the ingredients, or the alkaline material may be provided in combination with the aliphatic amino acid. For example, the alkali metal salts of the amino acids, such as potassium or sodium glycinate, may be used both for providing the amino acid and for providing the alkalinity.

The other essential ingredient for our preferred test reagent composition is lactose. Other stabilizing materials such as sucrose or dextrose may be used; however, we have found that gen erally they are not as desirable as lactose be cause they appear to have an inhibiting effect on color formation. That is to say, while these less desirable materials may prevent the negatives from turning gold and the positives from turning brown, the intensity of the lavender i reduced.

In addition to the four essential ingredients. diluents may be added as desired, in order to ob-, tain better tableting properties, improved color (i. e. whiteness), improved free-flowin properties, etc.

The exact proportions of the amino acid, soluble nitroprusside, alkaline material and lactose, are not-particularly critical within broad limits, and the ingredients may be employed in a rather wide range of proportions. However, as the pro portions of the ingredients in the diagnostic formulations are varied, it has been noted that the properties of the formulaiions are altered in one or more of the following respects:

1. The speed of reaction of the reagent composition with acetone pos t ve urines.

2. The sensitivity of the reagent detecting small quantities of acelone bodies.

3. The stability of the reagent formulations when stored under adverse enviromnental conditions.

When sodium nitroprusside is used as the water soluble nitroprusside in our diagnostic compositions, this ingredient should not comprise over approximately 5% of the total bulk of the mixture and should represent at least 0.04% by Weight of the total bulk. The preferred range of concentration for this ingredient is from 0.5 to 1 Other soluble nitroprussides are preferably used in molecularly equivalent concentration.

The relative proportions of disodium phosphates and glycine or their equivalents as indicated above, in the reagent compositions can vary quite Widely and still the reagent compositions will give satisfactory results with both acetone positive and acetone negative specimens. For instance, mixtures where the amount of glycine was about half that of the disodium phosphate gave clear cut tests. On the other hand, good tests were also obtained when the amount of glycine was only 1% of that of the disodium phosphate.

The concentration of the lactose is not particularly critical. Enough of the lactose should be used so that the beneficial results contributed by it are fully obtained. On the other hand, if too much lactose is employed, there will be a tendency to slow the reaction somewhat. Desirably, enough lactose is used in any particular formulation to obtain the advantages contributed by it While not using enough appreciably to slow the test reaction.

In general the optimum ranges of concentration of the four preferred ingredients are as follows:

Percent by weight When diluents or other inactive ingredients are employed, they do not serve to affect the above preferred concentrations of the required components except that the sodium nitroprusside or its equivalent should represent at least 0.04% by weight of the total bulk. It will of course be understood that in any formulation equivalent components or ingredients may be substituted in equivalent concentrations, as pointed out above.

Having thus fully described our invention and set forth formulations representing the preferred embodiments thereof, what is claimed as new is:

1. A diagnostic composition in solid dry form for detecting acetone bodies in urine, comprising from 0.04 to 5.0% of an alkali metal nitroprus- 8. A diagnostic composition for detecting acetone bodies in urine, comprising from 0.04 to 5.0% of a water-soluble nitroprusside, an aliphatic amino acid, an alkaline material, and a sugar selected from the group consisting of lactose, dextrose and sucrose.

4. A diagnostic composition in solid dry form for detecting acetone bodies in urine, comprising by weight, from 0.04-5.0% of sodium nitroprusside, from 1-20% of glycine, from 20-80% of disodium phosphate, and from 5 to 25% of lactose.

5. A diagnostic composition in solid dry form for detecdng acetone bodies in urine, comprising by weight, approximately 4.5 parts of glycine, approximately 0.5 part of sodium nitroprusside, approximately 47 parts of anhydrous disodium phosphate, and approximately 10 parts of lactose.

6. The composition of claim 5 containing in addition, approximately 36.5 parts of sodium borate, approximately 1.25 parts of corn starch, and approximately 0.25 parts of magnesium stearate.

7. Diagnostic tablets tableted from the composition called for in claim 4.

8. A diagnostic composition for detecting acetone bodies in urine, comprising from 0.04 to 5.0% of a water-soluble nitroprusside, lactose and a component selected from the group consisting of (a) a mixture of an alkaline material and an aliphatic amino acid and (b) an alkaline alkali metal salt of an aliphatic amino acid.

9. A diagnostic composition for detecting acetone bodies in urine comprising from 0.04 to 5.0% of a water-soluble nitroprusside, a member of the group consisting of (a) an alkaline material plus an aliphatic amino acid and (b) an alkaline alkali metal salt of an aliphatic amino acid, and a sugar in quantity sufficient to enhance the stability of color developed by said composition in the presence of acetone bodies.

RICHARD S. N ICHOLLS. DALE E. FONNER.

REFERENCES CITED The following references are of record in the file of this patent:

UNITED STATES PATENTS Number Name Date 2,171,962 Fortune Sept. 5, 1939 2,186,902 Fortune Jan. 9, 1940 2,283,262 Kamlet May 19, 1942 2,362,478 Galat Nov. 14, 1944 2,509,140 Free May 23, 1950 OTHER REFERENCES Gregory: Uses and Applications of Chemicals and Related Materials, vol. I, Reinhold Pub. Co., N. Y. 0., 1939, pg. 112, col. 2.

Kolthofi et al.: Acid Base Indicators, MacMillian 00., N. Y. 0., 1937, pgs. 247-252 (Inc.).

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2171962 *Dec 19, 1938Sep 5, 1939Lilly Co EliUrine albumin test
US2186902 *Apr 7, 1939Jan 9, 1940Lilly Co EliUrine acetone test
US2283262 *Oct 2, 1940May 19, 1942Miles LabDiagnostic composition and method
US2362478 *Dec 24, 1941Nov 14, 1944Denver Chemical Mfg CompanyReagent for testing for acetone
US2509140 *Mar 2, 1948May 23, 1950Miles LabTest reagent composition
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US2737501 *Oct 6, 1954Mar 6, 1956Cambridge Chemical Products CoDiagnostic preparation for the determination of serum bilirubin
US2824842 *Jun 9, 1954Feb 25, 1958Hirsh SulkowitchUrine calcium test
US2990253 *May 21, 1959Jun 27, 1961Miles LabDiagnostic composition
US3005794 *Aug 8, 1958Oct 24, 1961Rose John ErnestMethod of using and manufacturing plastic equivalent to organic materials
US3048475 *Jun 16, 1958Aug 7, 1962Miles LabMethod and diagnostic composition of detecting phenylketones
US3212855 *Aug 6, 1962Oct 19, 1965Miles LabDiagnostic device
US3880590 *Jun 21, 1974Apr 29, 1975Shionogi & CoTest strip for ketone bodies
US4147514 *Nov 21, 1977Apr 3, 1979Miles Laboratories, Inc.Test means and method for detecting ketone bodies
US4172049 *May 11, 1978Oct 23, 1979Behringwerke AktiengesellschaftControl-solution for diagnostic detection methods for substances contained in the urine
US4405721 *Mar 20, 1981Sep 20, 1983Behringwerke AktiengesellschaftDiagnostic agent for the detection of ketone bodies
US4970172 *Dec 22, 1986Nov 13, 1990Abbott LaboratoriesMethod and device for ketone measurements
US5071769 *Dec 17, 1987Dec 10, 1991Abbott LaboratoriesMethod and device for ketone measurement
US6583722Dec 12, 2000Jun 24, 2003Kimberly-Clark Worldwide, Inc.Wetness signaling device
US6603403Dec 12, 2000Aug 5, 2003Kimberly-Clark Worldwide, Inc.Remote, wetness signaling system
US8871521Mar 8, 2012Oct 28, 2014Akers Biosciences, Inc.Breath ketone detector
DE1153920B *Oct 9, 1958Sep 5, 1963Miles LabDiagnostisches Mittel zur Bestimmung von Ketonverbindungen in Koerperfluessigkeiten
WO2012122394A1 *Mar 8, 2012Sep 13, 2012Akers Biosciences, Inc.Breath ketone detector
Classifications
U.S. Classification436/128
International ClassificationG01N33/64
Cooperative ClassificationG01N33/64
European ClassificationG01N33/64